Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05970627 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Name: Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma — clinical trial record (NCT05970627)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorYu jiren

Started2023-07-28

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 1, 2023 (before its estimated July 28, 2026 completion). Its status may not reflect the trial's current state.

Yu jiren

5 trials monitored

See all monitored trials

Gastric Cancer

1,194 trials monitored

See 60 trials at risk

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

Trial Details

NCT Number	NCT05970627
Lead Sponsor	Yu jiren
Conditions	Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
Enrollment	30 participants
Start Date	2023-07-28
Primary Completion	2026-07-28 (estimated)
Study Completion	2029-07-28 (estimated)
Updated on ClinicalTrials.gov	2023-08-01